Fat Loss Peptides: The Complete Guide to AOD-9604, CJC-1295, and Tesamorelin

The Plateau Is Biological, Not Personal

You're not imagining it. The stubborn fat that won't budge despite months of caloric deficit and consistent cardio isn't a motivation problem — it's a biology problem. And the biology is specific.

At the cellular level, adipocytes in the lower abdomen, hips, and thighs express more alpha-2 adrenergic receptors than beta receptors. Alpha-2 activity inhibits lipolysis. Meanwhile, chronically elevated insulin — even mild post-meal elevations — actively suppresses hormone-sensitive lipase (HSL), the key enzyme that breaks down triglycerides inside fat cells. Add in cortisol's tendency to drive preferential visceral fat accumulation, and the GH decline that starts in your late 20s (reducing the pulsatile lipolytic signaling that mobilizes free fatty acids from adipose tissue), and you have a system that is mechanistically resistant to standard diet-and-cardio approaches.

Peptides that target fat loss are interesting precisely because they address root mechanisms, not symptoms. They don't burn more calories by making you move more. They work directly on the lipolytic machinery, the GH axis that drives fat mobilization, and the visceral adipose tissue biology that no amount of cardio can specifically target. This guide covers the three most evidence-supported fat loss peptides — AOD-9604, CJC-1295/Mod-GRF, and Tesamorelin — the biology that explains why each one works, and how they're combined in protocols that address all three nodes of the fat loss system simultaneously.

The Fat Loss Biology Framework

Understanding why these three peptides work requires understanding three distinct mechanisms that actually drive stubborn fat loss. Each peptide targets a different node — and that's the stack logic.

Mechanism 1: The GH/IGF-1 Axis and Lipolysis

Growth hormone is the body's most potent endogenous lipolytic agent. When GH binds its receptor on adipocytes, it activates a signaling cascade that leads to phosphorylation and activation of hormone-sensitive lipase (HSL). HSL is the rate-limiting enzyme for triglyceride breakdown inside fat cells — it cleaves stored fat into glycerol and free fatty acids (FFAs), which are then released into circulation for use as fuel.

The downstream signal that GH drives — IGF-1 — has a complex role: it mediates many of GH's anabolic effects in muscle and bone, but it also amplifies lipolytic activity through a separate pathway involving IGF-1 receptor signaling in adipocytes. The practical implication: restoring youthful GH pulse amplitude (which starts declining after age 25–30) restores the lipolytic signal that the system depends on for sustained fat mobilization.

This is the node that CJC-1295/Mod-GRF and Tesamorelin target. Both are GHRH analogs — they signal the pituitary to produce more GH, increasing pulse amplitude and driving the GH → HSL → lipolysis cascade. The difference is in the GH pulse profile they create and which fat depot they preferentially affect.

Mechanism 2: Visceral Adipose Tissue (VAT) — Its Own Biology

Visceral adipose tissue is not just "fat in a different location." It's metabolically distinct tissue with its own biology and its own danger profile.

VAT surrounds the internal organs and is highly hormonally active — it secretes pro-inflammatory adipokines (TNF-α, IL-6, resistin), releases FFAs directly into the portal circulation (where they immediately load the liver with lipid), and has high glucocorticoid receptor density, making it preferentially responsive to cortisol-driven accumulation. VAT is independently associated with insulin resistance, cardiovascular disease, hepatic steatosis, and metabolic syndrome at levels that subcutaneous fat is not.

The biology of VAT is particularly relevant because it has higher GH receptor density and higher lipolytic sensitivity to GH than subcutaneous fat. This is why GHRH analogs that restore GH pulsatility — and Tesamorelin specifically, with its FDA-validated VAT reduction data — are uniquely effective at reducing visceral fat specifically.

Tesamorelin targets this node most directly. Its Phase III RCT data (Falutz 2007, Falutz 2010) shows measurable, sustained visceral adipose tissue reduction in human subjects — the strongest clinical evidence for a fat loss peptide that exists.

Mechanism 3: Direct Lipolytic Activation Without the GH Signal

The third node is distinct from the GH axis entirely. Some fat deposits — particularly subcutaneous fat in the stubborn areas — have attenuated sensitivity to GH-driven lipolysis even when GH levels are optimal. This is where a direct lipolytic agent that bypasses the GH receptor becomes useful.

AOD-9604 targets this node. As the C-terminal fragment of hGH (residues 177–191), it retains the fat-metabolism activity of the full GH molecule — stimulating beta-3 adrenergic receptors on adipocytes and activating PPARα for fat oxidation — without activating the GH receptor itself. No IGF-1 signal. No anabolic spillover. No glucose dysregulation. Pure lipolytic activity, directly on fat cells, without the systemic hormone effects of full GH.

The stack logic: AOD-9604 covers the direct lipolytic node that GH axis peptides can't reach. CJC-1295/Mod-GRF covers the pulsatile GH restoration node (body composition and lean mass preservation). Tesamorelin covers the visceral fat and metabolic health node with the strongest clinical validation. Three peptides, three nodes, complete coverage of the fat loss biology that standard approaches can't touch.

Three Peptide Deep-Dives

AOD-9604

AOD-9604 — Anti-Obesity Drug 9604 — is a synthetic 16-amino-acid peptide representing the C-terminal fragment of human growth hormone: specifically residues 177–191 (sometimes numbered 176–191 depending on convention), with a tyrosine residue added at the N-terminus for metabolic stability. The full hGH molecule is 191 amino acids and does many things in the body — linear growth, IGF-1 stimulation, insulin antagonism, lipolysis, protein synthesis. AOD-9604 is the surgical extraction of one of those effects: the fat-burning activity, isolated from everything else.

Mechanism: Full hGH drives lipolysis primarily through GH receptor binding on adipocytes → cAMP signaling cascade → HSL activation. The C-terminal fragment (AOD-9604) works through a complementary but distinct pathway: beta-3 adrenergic receptor stimulation on adipocyte membranes. Beta-3 AR is the receptor class most associated with thermogenic fat burning and lipolysis — it's the target that older beta-agonist weight loss drugs (which had serious cardiovascular side effects) were trying to hit. AOD-9604 hits it from the peptide angle, with the receptor specificity that makes thermogenic agonists dangerous largely absent. Simultaneously, AOD-9604 activates PPARα (peroxisome proliferator-activated receptor alpha), a nuclear receptor that upregulates fatty acid oxidation gene expression in adipocytes and liver — not just mobilizing fat but increasing the machinery to burn what's been released.

The "fat-specific" framing is accurate in a precise sense: AOD-9604 produces no measurable IGF-1 elevation, no effect on blood glucose, no growth-promoting activity. In head-to-head comparisons in research models, full hGH produces both lipolytic and growth-promoting effects; AOD-9604 produces lipolytic effects only. For anyone who wants fat loss without the systemic hormonal signal of full GH — no fluid retention, no potential IGF-1 elevation concerns, no insulin sensitivity disruption — AOD-9604 is the cleanest option in the class.

Clinical evidence: The AOD-9604 research record starts with Ng et al. (2000) — the original characterization of the hGH fragment's fat-specific activity, demonstrating lipolysis stimulation without growth-promoting effects in animal models. Heffernan et al. (2001) extended this to an obesity model, showing significant fat reduction in obese rodents at doses that produced no changes in muscle, bone, or IGF-1. Ng et al. (2001) published data from obese rhesus monkeys — a closer human analog — showing visceral and subcutaneous fat reduction without metabolic disruption. Khosla et al. (2003) characterized the broader metabolic effects in adipose tissue, confirming the PPARα activation pathway. The Australian TGA (Therapeutic Goods Administration) granted IND (investigational new drug) status for obesity treatment, and Phase II clinical trials were completed in human subjects. No FDA approval for fat loss currently exists — AOD-9604 is a research compound in the US context — but the mechanism is among the most thoroughly validated for any peptide in the fat loss category.

Oral bioavailability: AOD-9604 is notable among peptides for demonstrated oral bioavailability in clinical trials — Phase II studies used oral tablet formulations and demonstrated measurable activity. Most research peptides (BPC-157 being an exception) are effectively inactivated by GI proteases before reaching systemic circulation. AOD-9604's short, stable C-terminal fragment structure appears to confer partial resistance to degradation that most longer peptides lack. In research contexts, both oral and subcutaneous routes have been used.

Best use case: Stubborn subcutaneous fat — lower abdomen, lower back, hips, thighs. Body recomposition where lean mass preservation is the priority (no anabolic IGF-1 signal means no concern about growth effects; you're targeting fat selectively). Best combined with a GHRH analog to simultaneously optimize the GH axis while AOD-9604 handles the direct lipolytic layer.

CJC-1295 / Mod-GRF (1-29) for Fat Loss

CJC-1295/Mod-GRF 1-29 is the GHRH analog workhorse of the GH optimization stack — and when the goal is fat loss specifically, the mechanism translates cleanly from GH axis restoration to lipolytic signaling.

Mechanism through a fat loss lens: GHRH (growth hormone-releasing hormone) is the hypothalamic signal that tells the pituitary to release GH. CJC-1295/Mod-GRF 1-29 is a stabilized synthetic version of GHRH(1-29), the active N-terminal fragment, modified for significantly extended half-life. When administered, it amplifies the pituitary's natural GH pulses — producing GH release events that are 2–3x larger than baseline. Those amplified GH pulses drive the HSL activation cascade described above: lipolysis, FFA release from adipose, hepatic fatty acid oxidation. The IGF-1 signal that follows also contributes to body composition improvement — not pure fat loss, but preferential fat reduction while lean mass is preserved or increased. This is the body composition vs. weight loss distinction that matters: the scale may not drop dramatically, but the mirror tells a different story as fat decreases and muscle is preserved.

The pulsatility argument: There are two versions of CJC-1295: one with DAC (Drug Affinity Complex) and one without (Mod-GRF 1-29). The DAC version extends half-life to several days, creating essentially continuous GHRH signal and flat GH elevation. For fat loss, this is suboptimal. GH is most potently lipolytic in the context of pulsatile release — high-amplitude discrete pulses followed by recovery periods. Continuous flat GH suppresses the somatostatin feedback that controls pulse architecture, blunting peak amplitude. Mod-GRF 1-29 (CJC-1295 without DAC) preserves pulsatility: injected in the 30-minute window before a GH pulse event (fasted morning, pre-sleep), it amplifies that specific pulse without disrupting the feedback loop. For fat loss protocols specifically, Mod-GRF is the preferred choice over DAC.

Timing: The two windows that matter are fasted morning — when insulin is lowest and GH pulses are sensitive to GHRH amplification — and pre-sleep, when the largest natural GH pulse of the day occurs during the first deep sleep stage. Pairing pre-sleep Mod-GRF with Ipamorelin (a ghrelin mimetic that provides the GHRP trigger input on the complementary receptor) produces the classic GHRH + GHRP synergy: combined GH pulse amplitude 8–12x baseline vs. either peptide alone (Smith 1997 synergy characterization).

Evidence: Alba et al. (2006) — a randomized controlled trial — demonstrated measurable GH pulse amplitude increases with Mod-GRF in healthy volunteers, with dose-dependent response. Teichman et al. (2006) provided dose-response data for extended-release formulations. Direct fat loss RCT data for CJC-1295/Mod-GRF specifically is limited — the body composition evidence is extrapolated from GH mechanism data and longer-term studies showing improved body composition with sustained GH optimization. This is an honest limitation compared to Tesamorelin's Phase III visceral fat data.

Best use case: Overall body recomposition — gradual lean mass preservation plus fat reduction over 12-week cycles. Works best stacked with Ipamorelin for synergistic GH pulse amplitude. Particularly effective at appetite normalization and metabolic rate support (GH's metabolic effects extend beyond pure lipolysis to insulin sensitivity modulation and metabolic rate support). The beginner-to-intermediate body recomposition workhorse.

Tesamorelin

Tesamorelin is the most clinically validated fat loss peptide available. This is not marketing positioning — it's a consequence of it being the only GHRH analog that has ever completed Phase III randomized controlled trials and received FDA approval. Every other peptide in this guide, and in the biohacker toolkit generally, exists in a different evidence tier. Tesamorelin is the benchmark.

FDA approval context: Tesamorelin was approved by the FDA in 2010 under the brand name Egrifta (Theratechnologies Inc.) for reduction of excess visceral abdominal fat in HIV-infected patients with lipodystrophy — a condition characterized by abnormal fat distribution including visceral fat accumulation. The mechanism of HIV-associated lipodystrophy involves GH/IGF-1 axis dysregulation that is mechanistically identical to the GH decline that drives visceral fat accumulation in aging and metabolic syndrome. The approval was granted because Phase III trials showed statistically significant, clinically meaningful reductions in visceral adipose tissue (VAT) measured by CT scan — the gold standard body composition measurement.

Mechanism: Tesamorelin is a full-length GHRH(1-44) analog — it uses the complete 44-amino-acid sequence of native GHRH with a trans-2-hexadecanoic acid (lipid group) added to the N-terminus. That lipid modification dramatically extends half-life compared to native GHRH (which degrades within minutes) and compared to CJC-1295 without DAC (active for ~30 minutes). The result is a GHRH signal that produces sustained GH elevation rather than acute pulsatile peaks — a different GH profile that appears particularly effective at reducing visceral fat specifically, possibly through GH receptor engagement in the highly GH-sensitive visceral adipose tissue depot.

Clinical data:

• Falutz et al. (2007) — first Phase III RCT, N=412 HIV patients with lipodystrophy. Tesamorelin 2mg/day vs. placebo for 26 weeks. Result: statistically significant VAT reduction by CT scan (−15.6% in the treatment arm vs. +2.6% in placebo; p<0.001). Secondary outcomes included IGF-1 normalization, triglyceride reduction, and quality of life improvements.
• Falutz et al. (2010) — 52-week extension data from the Phase III program. VAT reduction was sustained at 52 weeks in continuous-treatment arms. Discontinuation arm showed VAT returning toward baseline — establishing that the effect is dependent on continued treatment, not a permanent reset.
• Grinspoon et al. (2008) — focused on lipid profile outcomes. Tesamorelin treatment reduced triglycerides and improved HDL/LDL ratios, consistent with GH's favorable effects on hepatic lipid metabolism. This is the metabolic health node: reducing VAT addresses insulin resistance and metabolic syndrome risk at the source.

Visceral fat specifically: Why is Tesamorelin better than CJC-1295 for intra-abdominal fat? Several converging factors: (1) Tesamorelin's half-life profile creates more sustained GH elevation, which may be more effective at the GH receptor in visceral adipocytes specifically. (2) The Phase III data was specifically designed to measure and prove VAT reduction — so we know it works for this outcome at the clinical evidence level. (3) CJC-1295/Mod-GRF's body composition data is indirect and extrapolated; Tesamorelin's VAT reduction is directly measured by CT in 412 human subjects.

Regulatory reality: In the US, Tesamorelin (Egrifta) is FDA-approved as a prescription medication for lipodystrophy. Outside that indication, it exists in the same research compound context as other GH peptides. It is prescription-only — researchers working with it outside the approved indication are in the same regulatory territory as any other research peptide, just with an approved drug that happens to also be used in research settings.

Comparison at a Glance

Fat Loss Stack Protocols

Protocol 1: Body Recomposition Starter

Goal: Gradual recomposition — fat reduction while preserving or building lean mass.

Compounds:

• Mod-GRF 1-29 (CJC-1295 no DAC): 100mcg per injection
• Ipamorelin (cross-cluster): 200–300mcg per injection

Timing:

• AM dose: fasted, 30–60 minutes before breakfast or fasted cardio
• PM dose: 30–45 minutes before sleep (on an empty stomach — last meal 2+ hours prior)

Cycle: 12 weeks on / 4 weeks off

Rationale: This is the classic GHRH + GHRP stack — the single most established GH optimization protocol in research. Mod-GRF amplifies the GH pulse volume (the GHRH input); Ipamorelin provides the ghrelin-mimetic trigger (the GHRP input through GHS-R1a). Combined, they produce synergistic GH pulse amplitude (8–12x baseline, per Smith 1997) that neither produces alone. The fat loss effect is indirect but real: sustained GH pulse optimization drives HSL-mediated lipolysis across both subcutaneous and visceral depots, improves insulin sensitivity, and preserves lean mass through the IGF-1 signal. Ipamorelin is the cleanest GHRP — zero cortisol, zero prolactin, zero appetite stimulation — making it ideal for fat loss goals where hormonal cleanliness matters.

Best for: Anyone new to GH peptide stacking. Sustainable 12-week cycle with well-documented safety profile. Gradual improvement in body composition without aggressive hormone manipulation.

Protocol 2: Stubborn Fat Blitz

Goal: Target subcutaneous stubborn fat — lower abdomen, hips, lower back, thighs.

Compounds:

• AOD-9604: 300mcg per injection
• Mod-GRF 1-29: 100mcg per injection

Timing:

• AOD-9604: fasted pre-workout (15–30 minutes before cardio session); subcutaneous injection
• Mod-GRF: pre-sleep (30–45 minutes before bed, fasted)

Cycle: 8–12 weeks

Rationale: AOD-9604 is dosed pre-fasted-cardio because its beta-3 AR activation and direct lipolytic effect are most productive when insulin is low and FFAs can be oxidized during the subsequent exercise session. The fat mobilized by AOD-9604 needs somewhere to go — cardio in the fasted state provides the oxidative sink. Mod-GRF is reserved for the pre-sleep pulse, where it amplifies the largest natural GH pulse of the day without interfering with AOD-9604's direct lipolytic mechanism. These two compounds work on separate receptor pathways — AOD-9604's beta-3 AR mechanism vs. Mod-GRF's GHRH receptor — so there's no receptor competition and their effects are additive.

Best for: Intermediate users with a specific stubborn fat target. Particularly effective for the lower-body subcutaneous fat that resists standard diet approaches. Can be cycled after Protocol 1 for a more targeted phase.

Protocol 3: Visceral Fat + Metabolic Health

Goal: Reduce intra-abdominal fat, improve insulin sensitivity, improve lipid panel.

Compounds:

• Tesamorelin: 1–2mg per injection
• AOD-9604: 300mcg per injection

Timing:

• Tesamorelin: pre-sleep (30–45 minutes before bed, fasted) — following the Falutz trial dosing model
• AOD-9604: fasted pre-workout, morning

Cycle: 12 weeks (following Tesamorelin's evidence-based dosing from Phase III data)

Rationale: The Falutz Phase III trials used once-daily Tesamorelin dosing at the pre-sleep time point — that's the validated protocol. Tesamorelin's sustained GH elevation targets visceral adipose tissue through the GH receptor pathway. AOD-9604 adds the complementary direct lipolytic signal via beta-3 AR — hitting subcutaneous stubborn fat simultaneously via a non-overlapping mechanism. This protocol addresses both VAT (Tesamorelin's evidence-based sweet spot) and subcutaneous depots (AOD-9604's domain) in parallel.

Expected outcomes based on clinical data: Measurable VAT reduction (Falutz 2007 showed ~15% VAT reduction at 26 weeks), triglyceride improvement, insulin sensitivity markers. AOD-9604 contribution in human subjects is less precisely quantified — evidence is Phase II rather than Phase III — but the mechanistic rationale for additive effect is solid.

Best for: Users with meaningful visceral fat accumulation; metabolic syndrome risk markers; anyone with lipid panel concerns or insulin resistance. This is the most clinically grounded stack in this guide.

Protocol 4: Advanced Full-Stack Recomposition

Goal: Aggressive body recomposition with recovery support — all three fat loss nodes plus tissue repair.

Compounds:

• Tesamorelin: 1–2mg pre-sleep
• Mod-GRF 1-29: 100mcg fasted AM
• AOD-9604: 300mcg fasted pre-workout
• BPC-157: 250–500mcg daily (recovery support, cross-cluster with Repair & Recovery Hub)

Timing:

• Morning (fasted): Mod-GRF 1-29 + AOD-9604 pre-workout
• Pre-sleep (fasted): Tesamorelin
• BPC-157: subcutaneous, once daily (timing flexible — morning or evening)

Cycle: 12 weeks on / 4 weeks off. Stagger introduction if desired: start with Protocol 1 (Mod-GRF + Ipamorelin) for 4 weeks before adding Tesamorelin and AOD-9604.

Rationale: Full coverage of all three fat loss nodes simultaneously — direct lipolysis (AOD-9604), pulsatile GH restoration (Mod-GRF), and VAT-targeted sustained GH elevation (Tesamorelin). BPC-157 is added for recovery support: aggressive training combined with fat loss hormonal signaling puts real demands on connective tissue and systemic recovery. BPC-157's angiogenic (VEGF), GH receptor sensitization, and eNOS/NO pathway effects support recovery between sessions and protect against the overuse injury risk that comes with high-volume training during body recomposition phases. Cross-cluster stacking rationale: fat loss peptides drive the body composition outcome; repair peptides maintain the training capacity that generates that outcome. See the GH Peptides Complete Guide for expanded GH axis context.

Best for: Advanced users with experience across multiple peptide cycles who are comfortable managing three-compound stacks. Not a starting point — this is the aggressive recomposition protocol for people who've already run the basics and want the full toolkit deployed.

Honest Evidence Summary

Understanding where each compound sits on the evidence spectrum is important — these are research peptides, and overselling the data doesn't help anyone build a rational protocol.

AOD-9604: Strong preclinical data across multiple animal models (obese rodents, obese rhesus monkeys) with consistent fat-specific lipolytic activity and no growth-promoting effects. Phase II human trials were completed and showed safety and tolerability; TGA (Australia) granted IND status for obesity treatment. No current FDA approval for fat loss in the US. The mechanism is well-characterized at the receptor level, oral bioavailability is documented, and the fat-specific framing (no IGF-1, no glucose dysregulation) has been consistently validated. Evidence tier: Strong preclinical + early clinical, research compound context.

CJC-1295 / Mod-GRF 1-29: Solid human pharmacokinetic data (Alba 2006 RCT showing GH pulse amplitude increase). Body composition evidence is mechanistically inferred from GH axis physiology and longer-term studies of GH optimization — not from direct fat loss RCTs using CJC-1295 specifically. The GHRH receptor mechanism is one of the most well-characterized receptor systems in endocrinology. Evidence tier: Good PK data, body composition inferred from mechanism. Less direct fat loss RCT data than Tesamorelin.

Tesamorelin: The strongest evidence in the fat loss peptide class, period. Two Phase III RCTs (N=412, 26 weeks; extension to 52 weeks), FDA approval, direct VAT reduction measured by CT scan. Lipid profile improvements in Grinspoon 2008. This is what clinical validation looks like in the peptide world. Prescription-only in the US for its approved indication (HIV lipodystrophy); research compound context outside that indication. Evidence tier: Phase III FDA-approved. Most credible for visceral fat specifically.

Honest framing for all three: These are research peptides outside their approved indications (AOD-9604 has no approval; CJC-1295 has no approval; Tesamorelin is approved for lipodystrophy only, not general fat loss). The mechanisms are real and the research is credible — but that's a different statement from FDA-approved for body composition. Anyone running these in a research context should understand the distinction and approach protocols with appropriate rigor.

Conclusion: Three Mechanisms, One System

The fat loss biology framework maps cleanly onto three intervention points — and the three peptides in this guide cover all of them:

Node 1 (GH axis pulsatility + lean mass preservation): CJC-1295/Mod-GRF restores the GHRH → GH pulse → HSL → lipolysis cascade. It's the recomposition workhorse — preserving muscle while the GH signal mobilizes fat. Stack it with Ipamorelin for the synergistic GHRH + GHRP effect.

Node 2 (Visceral adipose tissue + metabolic health): Tesamorelin targets VAT with the most clinically validated mechanism in this space. Phase III data, FDA approval, measurable VAT reduction, lipid panel improvement. If metabolic health and intra-abdominal fat are the priority, Tesamorelin is the anchor.

Node 3 (Direct lipolysis + stubborn subcutaneous fat): AOD-9604 bypasses the GH receptor entirely and hits beta-3 AR directly — the fat-specific fragment of hGH without the systemic signal. It covers the stubborn subcutaneous depots that the GH axis approach alone doesn't fully address.

The four protocols above give you the entry points at every level — beginner recomposition through advanced full-stack. The reconstitution guide covers everything you need to know before your first injection: How to Reconstitute Peptides: Step-by-Step Guide.

Ready to Build Your Fat Loss Stack?

Peptide Stacking Guide — $14.99 → Complete fat loss, GH, repair, and longevity stacking protocols. Includes the full cycle structures, timing guides, and combination logic for every major peptide cluster — including the four protocols in this guide.

Peptide 101 Complete Bundle — $19.99 → The Beginner's Guide + Stacking Guide together — everything from "what is a peptide" through advanced multi-compound body recomposition stacks. The complete toolkit.